Myelodysplastic Syndromes
Precision medicine in MDS: tailoring treatment through molecular profiling
This VJHemOnc podcast explores how precision medicine is reshaping the management of myelodysplastic syndromes (MDS). Alex Bataller, MD, PhD, The…
Date: 7th August 2026
Top updates in MDS from ASH 2025: key trial updates and debated topics
In this podcast episode, leading experts share key updates in the management of myelodysplastic syndromes (MDS) from ASH 2025. Amer…
Date: 12th December 2025
Novel strategies and advances in the management and classification of MDS: insights from iwMDS 2025
This episode features discussions from the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held…
Date: 4th September 2025
iwMDS wrap-up: translating research into practice to optimize patient care
VJHemOnc recently attended the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held in Lisbon,…
Date: 18th July 2025
CHIP & CCUS: advances in understanding and should we treat these precursor conditions?
In this episode of the VJHemOnc podcast, we explore clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown…
Date: 20th June 2025
Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS
This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH)…
Date: 17th January 2025
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
This podcast features a discussion from the 6th International Workshop on Acute Leukemias (iwAL) 2024, which took place in Phoenix,…
Date: 6th November 2024
Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more
In myelodysplastic syndromes (MDS), chronic inflammation driven by the innate immune system plays a key role in disease progression. Signal…
Date: 12th August 2024
Novel developments in lower-risk MDS & important practical considerations when treating patients
In today’s VJHemOnc podcast, we will be sharing novel developments in lower-risk myelodysplastic syndromes (LR-MDS) and important practical considerations when treating patients….
Date: 15th July 2024
Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks
While there have been advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) in recent years, one major challenge that…
Date: 11th June 2024
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies,…
Date: 28th March 2024
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS;…
Date: 8th February 2024
